http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
( Shinya Taki ),( Hideyuki Tamai ),( Yoshiyuki Ida ),( Naoki Shingaki ),( Akira Kawashima ),( Ryo Shimizu ),( Kosaku Moribata ),( Takao Maekita ),( Mikitaka Iguchi ),( Jun Kato ),( Taisei Nakao ),( Ma 대한간학회 2018 Gut and Liver Vol.12 No.1
Background/Aims: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this therapy for elderly patients aged ≥75 years and to clarify whether an extremely high sustained virological response (SVR) rate can be achieved, even in a real-world setting when patients with resistance-associated substitutions (RASs) to nonstructural protein 5A (NS5A) inhibitors or prior simeprevir failure are excluded. Methods: Daclatasvir (60 mg) and asunaprevir (100 mg) were orally administered daily for 24 weeks. Patients without pre-existing NS5A RASs and simeprevir failure were enrolled in this study. Results: Overall, 110 patients were treated. The median age was 73 years old. The SVR rates of total patients, those aged ≥75 years, and those aged <75 years were 97% (107/110), 98% (46/47), and 97% (61/63), respectively. The treatment of two patients (2%) was discontinued because of adverse events. Conclusions: Daclatasvir with asunaprevir was a safe treatment, even in patients aged ≥75 years. When patients without pre-existing NS5A RASs and prior simeprevir failure were selected, an extremely high SVR rate could be achieved irrespective of age. (Gut Liver 2018;12:86-93)
Shinya Taki,Takao Maekita,Mayumi Sakata,Kazuhiro Fukatsu,Yoshimasa Maeda,Mikitaka Iguchi,Hidefumi Ito,Masayuki Kitano 대한소화기내시경학회 2019 Clinical Endoscopy Vol.52 No.6
Continuous duodenal levodopa/carbidopa intestinal gel delivery by a gastrostomy infusion system improves control of Parkinson’sdisease. The overall complication rates of percutaneous endoscopic gastrojejunostomy were reported to be 41% and 59% for immediateand delayed adverse events, respectively. A 72-year-old woman underwent percutaneous endoscopic gastrojejunostomy using thedelivery system noted above. Abdominal pain and vomiting occurred 3 months later. Esophagogastroduodenoscopy showed alongitudinal ulcer extending from the lower gastric body to the ileum end, with small intestinal telescoping. Colonoscopy showed alarge bezoar of food residue that was attached around the tip of the tube, reaching the ascending colon, which may have acted as ananchor. Thus, the gastric antrum and small intestine were shortened with telescoping. This complication was resolved by crushing thebezoar with forceps during colonoscopy and can be prevented by consuming a fiber-free diet and periodic exchanges of the tube usingesophagogastroduodenoscopy.
A Rare Case of a White-Furred Ileocecal Valve
Shinya Taki,Takao Maekita,Masayuki Kitano 대한소화기내시경학회 2021 Clinical Endoscopy Vol.54 No.4
BOOST YOUR LEARNING WITH QUIZ